Trial Profile

Safety and Preliminary Clinical Efficacy of MT-302 with CapOx based regimens in metastatic esophagogastric cancer (SPaCE-MT)

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 15 Jul 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

28 Oct 2025 According to a CREATE Medicines media release, Professor Hanneke van Laarhoven is the leading scientist on the trial and a Medical Oncologist and Head of the Department of Medical Oncology at Amsterdam UMC, Cancer Center in the Netherlands
28 Oct 2025 Status changed to recruiting.
28 Oct 2025 According to a CREATE Medicines media release, today that Amsterdam University Medical Center (Amsterdam UMC) has dosed the first patient in the SPaCE-MT clinical trial, for treatment of advanced gastroesophageal cancer.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com